ClinicalTrials.gg
CompletedNCT07878000Updated Oct 16, 2026

Subtalar & Talonavicular Arthrodesis v.s Subtalar & Naviculocuniform Arthrodesis for Progressive Collapsing Foot Deformity

An interventional study of Subtalar and talonavicular arthrodesis and subtalar and naviculocuneiform arthrodesis in Foot Deformity and Arthrodesis, sponsored by Cairo University. Completed at 1 site in Egypt. Open to participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled May 2025, registered Oct 2026).
Updated Oct 16, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
53
Allocation
Not applicable
Ages
20 Years to 50 Years
Sex
All
01

Study summary

This study compares two surgical procedures for adults with painful, rigid progressive collapsing foot deformity, also known as rigid flatfoot, whose symptoms have persisted despite at least six months of nonsurgical treatment.

Both procedures fuse the subtalar joint, a joint below the ankle. One procedure also fuses the talonavicular joint, while the other fuses the naviculocuneiform joint. These joints are located at different points along the inner arch of the foot. Joint fusion joins bones together to improve foot alignment and stability. The procedure is selected according to where the foot's inner arch has collapsed.

The study evaluates changes in foot alignment on standing X-rays, foot and ankle function, physical function, and quality of life. It also compares operating time, bone healing, and complications. Both groups receive the same postoperative care and rehabilitation, with follow-up assessments during recovery and approximately one year after surgery.

The aim is to compare the outcomes of these two surgical approaches when each is selected according to the location of the deformity.

02

Conditions studied

  • Foot Deformity
  • Arthrodesis
03

In context

Foot Deformities

62 studies on the registry are indexed under Foot Deformities; 13 are open to participants now.

This study's enrollment of 53 is below the median of 60 across 28 interventional studies indexed under Foot Deformities.

Browse Foot Deformities studies →

Lead sponsor

Cairo University is the lead sponsor of 4,909 studies on the registry; 1,445 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: skeletal maturity > 18 yrs
  • Sex: Both males and females.
  • The patient was diagnosed with rigid pes planovalgus, corresponding to Progressive Collapsing Foot Deformity (PCFD) type 2(ABC) - a rigid Stage II deformity characterized by hindfoot valgus, midfoot abduction, and medial column instability. Under the earlier Johnson and Strom / Myerson classification, this presentation would correspond to Stage III disease, defined by fixed hindfoot valgus and forefoot abduction with degenerative articular change.
  • Deformity apex-matched clinical decision (talonavicular apex → ST+TN; naviculocuneiform apex → ST+NC)

Exclusion criteria

Exclusion Criteria:

  • Skeletally immature patients
  • Charcot arthropathy,
  • Rheumatoid arthritis.
  • Prior surgery at the NC site
  • Patients with stage IV PTT dysfunction
  • Infection
  • Asymptomatic patients
  • Peripheral vascular disease
  • Uncontrolled diabetes mellitus
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Active comparator
    Group A: ST+TN

    Subtalar and talonavicular arthrodesis

    Procedure: Subtalar and talonavicular arthrodesis

  • Active comparator
    Group B: ST+NC

    subtalar and naviculocuneiform arthrodesis

    Procedure: subtalar and naviculocuneiform arthrodesis

Interventions

  • ProcedureSubtalar and talonavicular arthrodesis

    Subtalar and talonavicular arthrodesis: Surgical fusion of the subtalar and talonavicular joints to stabilize the hindfoot, correct deformity, and relieve pain.

  • Proceduresubtalar and naviculocuneiform arthrodesis

    Subtalar and naviculocuneiform arthrodesis: Surgical fusion of the subtalar and naviculocuneiform joints to stabilize the foot, correct deformity, and relieve pain.

06

What researchers measure

Primary outcomes

  1. AOFAS

    The AOFAS ankle-hindfoot score assesses pain, function, and alignment. Scores range from 0 to 100, with higher scores indicating better outcomes. Change is calculated as the postoperative score minus the preoperative score. Mean changes are compared between the subtalar plus talonavicular arthrodesis group and the subtalar plus naviculocuneiform arthrodesis group.

    Time frame: 1 day

07

Study locations

1 site
  • Cairo University
    Al-Manial, Cairo Governorate 11562, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Aug 2026, 15 months.

Of 14 interventional studies with no phase under Foot Deformities, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 15. This study's 15 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2026
First posted
Oct 16, 2026
StartActual
May 1, 2025
Primary completionActual
Aug 1, 2026
CompletionActual
Aug 20, 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07878000
Lead sponsor
Cairo University
Responsible party
Mostafa Gamal Reyad (Dr, Cairo University) — Principal investigator
First posted
Oct 16, 2026
Start date
May 1, 2025
Primary completion
Aug 1, 2026
Completion
Aug 20, 2026
Last update
Oct 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion